{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:08:16Z","timestamp":1790060896964,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ejca.2013.07.141","type":"journal-article","created":{"date-parts":[[2013,8,10]],"date-time":"2013-08-10T16:45:18Z","timestamp":1376153118000},"page":"3863-3871","source":"Crossref","is-referenced-by-count":55,"title":["\u03b2-Blocker use and all-cause mortality of melanoma patients: Results from a population-based Dutch cohort study"],"prefix":"10.1016","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct00888797","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01308944","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"E.","family":"Livingstone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Hollestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.P.","family":"van Herk-Sukel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"van de Poll-Franse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nijsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2013.07.141_b0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2013.07.141_b0010","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2013.07.141_b0015","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2013.07.141_b0020","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2013.07.141_b0025","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1055-9965.EPI-11-0249","article-title":"Beta-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study","volume":"20","author":"Lemeshow","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.ejca.2013.07.141_b0180","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pros.22564","article-title":"Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy","volume":"73","author":"Grytli","year":"2013","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.ejca.2013.07.141_b0185","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2012.07.102","article-title":"Impact of beta blockers on epithelial ovarian cancer survival","volume":"127","author":"Diaz","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2013.07.141_b0040","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archinternmed.2011.131","article-title":"Treatment with beta-blockers and reduced disease progression in patients with thick melanoma","volume":"171","author":"De Giorgi","year":"2011","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.ejca.2013.07.141_b0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1758834012439738","article-title":"Beta-adrenergic blocking drugs in breast cancer: a perspective review","volume":"4","author":"Barron","year":"2012","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2013.07.141_b0050","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm1447","article-title":"Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma","volume":"12","author":"Thaker","year":"2006","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.ejca.2013.07.141_b0055","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-10-0522","article-title":"The sympathetic nervous system induces a metastatic switch in primary breast cancer","volume":"70","author":"Sloan","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2013.07.141_b0060","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbi.2008.10.005","article-title":"Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression","volume":"23","author":"Yang","year":"2009","journal-title":"Brain Behav Immun"},{"issue":"2","key":"10.1016\/j.ejca.2013.07.141_b0065","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2133.2010.09848.x","article-title":"Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action","volume":"163","author":"Storch","year":"2010","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.ejca.2013.07.141_b0070","first-page":"2866","article-title":"Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers","volume":"61","author":"Masur","year":"2001","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2013.07.141_b0075","first-page":"1669","article-title":"The beta-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kappaB signaling","volume":"24","author":"Liao","year":"2010","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.ejca.2013.07.141_b0080","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejca.2009.09.010","article-title":"New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO record linkage system","volume":"46","author":"van Herk-Sukel","year":"2010","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2013.07.141_b0085","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ije\/22.3.369","article-title":"Completeness of cancer registration in Limburg, The Netherlands","volume":"22","author":"Schouten","year":"1993","journal-title":"Int J Epidemiol"},{"issue":"2","key":"10.1016\/j.ejca.2013.07.141_b0090","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/jech.46.2.136","article-title":"Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts","volume":"46","author":"Herings","year":"1992","journal-title":"J Epidemiol Community Health"},{"issue":"5","key":"10.1016\/j.ejca.2013.07.141_b0095","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0895-4356(97)00040-1","article-title":"Validation of pharmacy records in drug exposure assessment","volume":"50","author":"Lau","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ejca.2013.07.141_b0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2710.2008.00878.x","article-title":"Prevalence and determinants of pharmacy shopping behaviour","volume":"33","author":"Buurma","year":"2008","journal-title":"J Clin Pharm Ther"},{"issue":"36","key":"10.1016\/j.ejca.2013.07.141_b0105","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.07.141_b0110","unstructured":"WHO. Definition and general considerations. In: Methodology WCCfDS, editor. Oslo: WHO; 2009."},{"issue":"1","key":"10.1016\/j.ejca.2013.07.141_b0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00125-011-2312-4","article-title":"Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study","volume":"55","author":"Ruiter","year":"2012","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.ejca.2013.07.141_b0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10654-010-9451-7","article-title":"Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies","volume":"25","author":"Stricker","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"10.1016\/j.ejca.2013.07.141_b0125","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdm498","article-title":"Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site","volume":"19","author":"de Vries","year":"2008","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2013.07.141_b0130","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/annonc\/mdm087","article-title":"Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands","volume":"18","author":"de Vries","year":"2007","journal-title":"Ann Oncol"},{"issue":"2\u20133","key":"10.1016\/j.ejca.2013.07.141_b0135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0010-468X(85)90011-X","article-title":"A computer program package for relative survival analysis","volume":"19","author":"Hakulinen","year":"1985","journal-title":"Comput Program Biomed"},{"issue":"4","key":"10.1016\/j.ejca.2013.07.141_b0140","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.ejca.2013.07.141_b0145","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2013.07.141_b0150","doi-asserted-by":"crossref","first-page":"483493","DOI":"10.1155\/2010\/483493","article-title":"Stress as a possible mechanism in melanoma progression","volume":"2010","author":"Sanzo","year":"2010","journal-title":"Dermatol Res Pract"},{"issue":"11","key":"10.1016\/j.ejca.2013.07.141_b0155","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jclinepi.2012.04.008","article-title":"Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias","volume":"65","author":"Wolkewitz","year":"2012","journal-title":"J Clin Epidemiol"},{"issue":"19","key":"10.1016\/j.ejca.2013.07.141_b0160","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ejca.2013.07.141_b0165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ijc.20410","article-title":"Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs","volume":"112","author":"Lang","year":"2004","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2013.07.141_b0170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1007784109255","article-title":"Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors","volume":"13","author":"Smith","year":"1999","journal-title":"Cardiovasc Drugs Ther"},{"issue":"11","key":"10.1016\/j.ejca.2013.07.141_b0175","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1586\/era.12.118","article-title":"Beta-adrenergic-blocking drugs and melanoma: current state of the art","volume":"12","author":"De Giorgi","year":"2012","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491300717X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491300717X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T16:12:29Z","timestamp":1563639149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491300717X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":35,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S095980491300717X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.07.141","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}